Abstract
Six patients with recurrent and/or refractory acute nonlymphocytic leukemia (ANLL) were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) and cytotoxic agents administered simultaneously. Neither of the two patients who received cytosine arabinoside (ara-C) in combination with G-CSF achieved complete remission. The other four patients, who received multi-drug combination therapy together with G-CSF, all achieved complete remission. No major side effects due to G-CSF were observed. These results demonstrated that the effects of G-CSF in enhancing the sensitivity of leukemic cells to cytotoxic agents and accelerating the recovery of leukocytes could lead to its possible use in the treatment of ANLL.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cell Cycle / drug effects
-
Cytarabine / administration & dosage
-
Cytarabine / analogs & derivatives
-
Cytarabine / therapeutic use*
-
Daunorubicin / administration & dosage
-
Drug Evaluation
-
Drug Resistance
-
Drug Synergism
-
Etoposide / administration & dosage
-
Female
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / therapy
-
Leukocyte Count / drug effects
-
Male
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Remission Induction
Substances
-
Immunologic Factors
-
Recombinant Proteins
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
Etoposide
-
enocitabine
-
Mitoxantrone
-
Daunorubicin